These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29386431)

  • 1. [Safe Use of Recent New Drugs-Current Status and Challenges].
    Ohashi Y
    Yakugaku Zasshi; 2018; 138(2):177-183. PubMed ID: 29386431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Making Patient-focused Information Provision a Reality: One Company's Approach].
    Takemoto S
    Yakugaku Zasshi; 2018; 138(3):315-323. PubMed ID: 29503422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk/Benefit Communication: International Developments and Prospects for the Future].
    Yamamoto M
    Yakugaku Zasshi; 2018; 138(3):299-306. PubMed ID: 29503420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Pharmaceuticals and Medical Devices Agency's Approach to Facilitate Risk Communication and Its Challenges].
    Kondo E; Torii M; Oba I; Okamoto M
    Yakugaku Zasshi; 2018; 138(3):307-314. PubMed ID: 29503421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacovigilance in pharmacy practice].
    Duquet N
    J Pharm Belg; 2011 Dec; (4):97-103. PubMed ID: 22299235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance and communicating safety information.
    Drug Ther Bull; 2012 Dec; 50(12):138-40. PubMed ID: 23241564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacists contribute to the safety of medicines].
    Nishihara S
    Yakugaku Zasshi; 2011; 131(6):865-9. PubMed ID: 21628969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
    Inácio P; Airaksinen M; Cavaco A
    Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Survey of Literature on the Development of an Evidence Database for Hospital-prepared Drugs in Japan].
    Momo K
    Yakugaku Zasshi; 2018; 138(6):753-756. PubMed ID: 29863041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacovigilance of biopharmaceuticals: challenges remain.
    Giezen TJ; Mantel-Teeuwisse AK; Leufkens HG
    Drug Saf; 2009; 32(10):811-7. PubMed ID: 19722725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European pharmacovigilance: increasingly outsourced to drug companies.
    Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current Status of Community Pharmacies: Expectations as a Health Information Hub, the Enforcement of Revised Pharmaceutical and Medical Device Act, and a New Role as Stakeholders].
    Saito M
    Yakugaku Zasshi; 2016; 136(2):245-9. PubMed ID: 26831801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk communication efforts regarding drug safety in the US and EU, and Japan].
    Yamamoto M
    Yakugaku Zasshi; 2012; 132(5):533-48. PubMed ID: 22687688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug safety--from patients' perspective].
    Kitazawa K
    Yakugaku Zasshi; 2011; 131(6):881-3. PubMed ID: 21628972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PharmActa: Personalized pharmaceutical care eHealth platform for patients and pharmacists.
    Spanakis M; Sfakianakis S; Kallergis G; Spanakis EG; Sakkalis V
    J Biomed Inform; 2019 Dec; 100():103336. PubMed ID: 31689550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical risk management in Turkey: the first national overview.
    Aydinkarahaliloglu ND; Aykac E; Kasap Y; Durmus N; Babacanoglu C; Basgut CE; Artiran G; Kerman S
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):344-50. PubMed ID: 23994623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.